The brepocitinib dermatomyositis approval landed on 27 August 2026. It is the first shift in a treatment field that has barely moved in decades. The US Food and Drug Administration cleared LISRAYA, an oral dual TYK2 and JAK1 inhibitor, for adults with dermatomyositis. Priovant Therapeutics, a Roivant company, said the medicine became available in the United States immediately. Regulators described it as the first approved oral treatment option for the disease. For rheumatology and dermatology teams, the practical question is now prescribing, not proof of concept.
What the brepocitinib dermatomyositis approval covers
The FDA approved LISRAYA 30 mg for the treatment of adults with dermatomyositis. It is taken once daily as a tablet. The agency granted the application Orphan Drug and Priority Review designations. In its announcement, the FDA called the product the first approved oral treatment option for these patients.
That wording matters. Dermatomyositis is not an untreated disease in regulatory terms. Octapharma secured FDA approval of Octagam 10 per cent, an intravenous immunoglobulin, for adult dermatomyositis in 2021. What was missing was a targeted oral option.
Priovant goes further in its own language. The company describes LISRAYA as the first and only targeted therapy approved for dermatomyositis. It also calls the medicine a first-in-class TYK2 and JAK1 inhibitor. Both claims sit in the company’s approval statement.
Nikolay Nikolov framed the gap plainly in the agency’s announcement. He is Director of the Office of Immunology and Inflammation in the FDA’s Center for Drug Evaluation and Research. “For too long, patients with dermatomyositis have faced a significant unmet need,” he said.
The standard of care being displaced
Dermatomyositis is a rare autoimmune disease. It attacks skeletal muscle and skin at the same time. Patients typically present with proximal muscle weakness and a distinctive rash. Adults with the condition often face disability, disfigurement and persistent pain.
Management has leaned on corticosteroids for generations. Conventional immunosuppressants and intravenous immunoglobulin sit alongside them. None of those options was designed for the disease mechanism. That is the gap a targeted oral agent is meant to close.
Ruth Ann Vleugels of Mass General Brigham and Harvard Medical School described the burden directly. She is first author on the VALOR paper. Her comments were issued in Priovant’s approval announcement. “Dermatomyositis affects nearly every aspect of a patient’s life,” she said. She added that the approval marks a turning point for patients living with the condition.
Inside the VALOR trial evidence
The approval rests on VALOR, a phase 3 study registered as NCT05437263. The trial randomised 241 adults across 90 sites globally. Patients received brepocitinib 30 mg daily, brepocitinib 15 mg daily, or placebo. Randomisation followed a one to one to one design. The double-blind treatment period ran for 52 weeks. Corticosteroid tapering was mandated by protocol from week 12. VALOR enrolled patients with refractory disease, most having failed multiple prior treatments. The approved label carries no restriction by disease activity, presentation or prior treatment. That gap between trial population and label breadth will shape early prescribing.
The primary endpoint was the Total Improvement Score at week 52. That composite draws on six core myositis disease activity measures. The 30 mg arm delivered a 15.3 point greater mean improvement than placebo. The result carried a P value below 0.001. The 15 mg dose did not separate from placebo. That halted further hierarchical testing, and only the 30 mg dose was approved. Findings appeared in the New England Journal of Medicine in March 2026.
Steroid tapering results
Steroid sparing is where the commercial argument sharpens. Priovant reported that 55 per cent of treated patients reached moderate or better improvement while taking minimal or no steroids. The placebo figure was 30 per cent.
Some patients entered the trial on at least 7.5 mg per day of corticosteroids. Of those, 62 per cent tapered to 2.5 mg per day or less. The placebo comparator was 38 per cent. Full discontinuation was achieved by 45 per cent on treatment against 29 per cent on placebo. Long-term steroid exposure carries well-documented harms, so these numbers speak directly to practice.
Skin disease outcomes
Skin-specific outcomes were published separately in JAMA Dermatology in August 2026. At week 52, 61.7 per cent of the 30 mg group achieved a clinically meaningful CDASI activity response. The placebo figure was 44.3 per cent, at P equals 0.04. Functional skin remission means a CDASI activity score of 5 or below. Among patients with at least moderate skin disease at baseline, it reached 43.5 per cent. The placebo figure in that group was 20.8 per cent.
Victoria P. Werth is Professor of Dermatology and Medicine at the University of Pennsylvania. Priovant also describes her as a lead VALOR investigator. She set out why the skin findings matter, in the company’s announcement. “Skin disease is a major and often underappreciated driver of morbidity in dermatomyositis,” she said.
A boxed warning that shapes prescribing
LISRAYA carries the JAK inhibitor class boxed warning. It covers serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. The label also flags gastrointestinal perforation, hypoglycaemia in diabetic patients and laboratory abnormalities. It does not recommend use alongside other JAK inhibitors, other TYK2 inhibitors or biologic DMARDs.
The most common adverse reactions were upper respiratory tract infection, headache, fatigue, urinary tract infection and nausea. Bronchitis, arthralgia, diarrhoea and influenza also featured on the list.
Serious infections reached 9.9 per cent on the 30 mg dose against 1.3 per cent on placebo. No opportunistic infections were reported and there were no deaths in either arm. Priovant said those infection events resolved with medical management. Malignancies, cardiovascular events and thromboembolic events occurred more often among placebo recipients. The trial authors do not read that as a protective drug effect. They attribute it to the baseline risks of dermatomyositis itself. They also point to the immunosuppressants, particularly systemic steroids, used to treat it. Prescribers will still weigh a class warning against a rare disease population with limited alternatives.
Why the approval matters commercially
Priovant was established in September 2021 as a Roivant and Pfizer venture. Pfizer holds a 25 per cent equity interest in the company. Pfizer licensed global development rights to oral and topical brepocitinib to Priovant. US and Japan commercial rights formed part of the same transaction.
Roivant had already signalled that launch readiness was on track by the end of September 2026. The company reported consolidated cash and marketable securities of 3.9 billion dollars at 30 June 2026. That figure appeared in its quarterly update published on 6 August. Approval then arrived ahead of the third quarter target action date.
Ben Zimmer, Chief Executive Officer of Priovant, called the decision a landmark for patients. “Today’s approval of LISRAYA marks a historic moment for the dermatomyositis community,” he said.
Priovant did not disclose a US list price in its approval announcement. Executives put the figure at 35,000 dollars for a 30-day supply on an investor call the next day. That equates to roughly 420,000 dollars a year at list, before discounts or rebates. The company said distribution runs through a limited network of specialty pharmacies. Priovant also runs a patient support programme. It says eligible patients may pay as little as zero dollars a month through that scheme. TD Cowen has put the opportunity across all brepocitinib indications at 5 to 10 billion dollars. That figure was reported by Endpoints News on the day of approval.
UK and European access remains undefined
The brepocitinib dermatomyositis approval leaves UK timing unresolved. Neither Priovant nor Roivant has published a European or UK filing timeline. That covers both the European Medicines Agency and the MHRA. The approval statement, the priority review announcement and the most recent quarterly update are all silent on ex-US submissions. There is a structural reason for that silence. Priovant holds commercial rights in the United States and Japan only. Pfizer retained certain commercial rights outside those markets when it licensed the asset. Any UK or European launch would therefore most likely be a Pfizer decision.
That silence has practical consequences. UK clinicians managing adult dermatomyositis have no date to plan around. British Society for Rheumatology guidance on idiopathic inflammatory myopathy still frames management around corticosteroids and conventional immunosuppressants.
Scale is part of the difficulty. A systematic review by Meyer and colleagues appeared in Rheumatology. It put inflammatory myopathy incidence at 1.16 to 19 cases per million per year. Reported prevalence ranged from 2.4 to 33.8 per 100,000. Dermatomyositis is a subset of that already small group. Small populations complicate commercial planning outside the largest markets.
What to watch next
Brepocitinib is not a single-indication asset. Roivant expects phase 3 topline data in non-infectious uveitis during the second half of 2026. A phase 3 study in cutaneous sarcoidosis, BEACON+, has begun enrolling. It targets around 140 patients across roughly 70 global sites. Topline results are anticipated in 2028. A phase 2b/3 programme in lichen planopilaris is also progressing.
Three things will define the next year. The first is real-world uptake against the boxed warning. The second is whether payers accept a targeted oral agent in a disease long managed with generics. The third is when, or whether, European and UK filings appear. Our coverage of FDA drug approval decisions tracks the wider decision calendar.
For now, one fact stands. The brepocitinib dermatomyositis approval gives adults in the United States a targeted oral option. It is the first of its kind.
